Speed generic drugs to market.

Marie Gluesenkamp Perez · Washington · Democratic

policy impact 0.57 specificity 0.77 extraction confidence 95%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Contest this claim

Occurrences

Evidence

unverified · Source version 26777 · locator unknown

Sponsor: Rep. Perez, Marie Gluesenkamp [D-WA-3]. Latest Action: House - 11/10/2023 Referred to the Subcommittee on Innovation, Data, and Commerce. This bill has the status Introduced. Official title: To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Perez introduced a bill directly aimed at speeding generic and biosimilar market entry by banning pay-for-delay deals, but Congress.gov still lists the measure only as introduced with its last action a subcommittee referral. No enactment or House passage is shown, so the commitment remains unresolved as of the refresh window.

unresolved same_term A for effort

All Information for H.R.6275 - Protecting Consumer Access to Generic Drugs Act of 2023
secondary · model gpt-5.5 · confidence 96%

Contest this evidence item

unverified · Source version 26778 · locator unknown

Rep. Marie Gluesenkamp Perez, along with Reps. Sean Casten and Gerry Connolly, introduced the Protecting Consumer Access to Generic Drugs Act of 2023. The release says the bill would end harmful pay-for-delay practices and provide FTC enforcement authority so people can access lower-priced generic drugs.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Her office announced concrete legislative action matching the promise: a bill to address patent-settlement delays that keep generic drugs out of the market. This is meaningful effort, but not proof of delivery because the bill had not become law.

partial same_term A for effort

Gluesenkamp Perez, Casten, Connolly Introduce Bill to Support Access to Lower-Priced Generic Drugs
secondary · model gpt-5.5 · confidence 94%

Contest this evidence item

unverified · Source version 26779 · locator unknown

GovInfo lists H.R. 6275 as introduced in House, sponsored by Marie Gluesenkamp Perez, with the full title: To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The authenticated bill text confirms Perez’s legislative proposal was specifically designed to speed generic and biosimilar entry by prohibiting compensation-for-delay arrangements. It supports partial progress, not completed delivery.

partial same_term A for effort

H.R. 6275 (IH) - Protecting Consumer Access to Generic Drugs Act of 2023
secondary · model gpt-5.5 · confidence 93%

Contest this evidence item

unverified · Source version 61260 · locator unknown

Status: Introduced on November 7 2023 - 25% progression, died in committee Action: 2023-11-10 - Referred to the Subcommittee on Innovation, Data, and Commerce.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Perez's H.R. 6275 was a concrete same-term effort to address delayed generic entry, but it died in committee after referral and did not become law.

never same_term A for effort

US HB6275 | 2023-2024 | 118th Congress | LegiScan
secondary · model gpt-5.5 · confidence 90%

Contest this evidence item

unverified · Source version 61262 · locator unknown

Last Action Date Listed April 10, 2025 Actions Reported by Mr. Grassley, with an amendment

Unverified model/legacy excerpt; not proof. AI summary (separate from source): A similar later-term federal pay-for-delay bill remains only reported in the Senate, not enacted, and is not Perez-sponsored, so it does not show candidate-creditable delivery.

unresolved later_term

S. 1096 (RS) - Preserve Access to Affordable Generics and Biosimilars Act - BILLS-119s1096rs | Content Details | GovInfo
secondary · model gpt-5.5 · confidence 88%

Contest this evidence item

Assessments

Public state: unverified As of unknown · legacy_unverified · . Original AI recommendation (not independently established): never. unknown A for effort

Perez made a serious same-term legislative attempt by sponsoring H.R. 6275, the Protecting Consumer Access to Generic Drugs Act of 2023, to ban pay-for-delay deals that delay generic and biosimilar entry. But the measure did not advance beyond introduction/subcommittee referral in the 118th Congress, and there is no enacted, candidate-creditable federal outcome showing the promise was delivered. Introduction without passage or implementation is effort, not fulfillment.

provider codex_cli · model gpt-5.5 · confidence 94%